Cargando…

Efficacy and safety of abobotulinumtoxinA for upper limb spasticity in children with cerebral palsy: a randomized repeat‐treatment study

AIM: To assess the efficacy and safety of repeat abobotulinumtoxinA injections in reducing upper limb spasticity in children with cerebral palsy (CP). METHOD: This was a double‐blind, repeat‐cycle study (NCT02106351) in children with CP (2–17y). Children were randomized to receive 2U/kg (control), 8...

Descripción completa

Detalles Bibliográficos
Autores principales: Delgado, Mauricio R, Tilton, Ann, Carranza‐Del Río, Jorge, Dursun, Nigar, Bonikowski, Marcin, Aydin, Resa, Maciag‐Tymecka, Iwona, Oleszek, Joyce, Dabrowski, Edward, Grandoulier, Anne‐Sophie, Picaut, Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8048784/
https://www.ncbi.nlm.nih.gov/pubmed/33206382
http://dx.doi.org/10.1111/dmcn.14733
_version_ 1783679294328799232
author Delgado, Mauricio R
Tilton, Ann
Carranza‐Del Río, Jorge
Dursun, Nigar
Bonikowski, Marcin
Aydin, Resa
Maciag‐Tymecka, Iwona
Oleszek, Joyce
Dabrowski, Edward
Grandoulier, Anne‐Sophie
Picaut, Philippe
author_facet Delgado, Mauricio R
Tilton, Ann
Carranza‐Del Río, Jorge
Dursun, Nigar
Bonikowski, Marcin
Aydin, Resa
Maciag‐Tymecka, Iwona
Oleszek, Joyce
Dabrowski, Edward
Grandoulier, Anne‐Sophie
Picaut, Philippe
author_sort Delgado, Mauricio R
collection PubMed
description AIM: To assess the efficacy and safety of repeat abobotulinumtoxinA injections in reducing upper limb spasticity in children with cerebral palsy (CP). METHOD: This was a double‐blind, repeat‐cycle study (NCT02106351) in children with CP (2–17y). Children were randomized to receive 2U/kg (control), 8U/kg, or 16U/kg abobotulinumtoxinA injections into the target muscle group (wrist or elbow flexors) and additional muscles alongside occupational therapy via a home‐exercise therapy program (HETP; minimum five 15min sessions/wk). Children received 8U/kg or 16U/kg plus HETP in cycles 2 to 4. RESULTS: During cycle 1, 210 children (126 males, 84 females; mean age [SD] 9y [4y 5mo], range 2–17y; n=70/group) had at least one upper limb abobotulinumtoxinA injection and 209 complied with the HETP. At week 6 of cycle 1, children in the 8U/kg or 16U/kg groups had significantly lower Modified Ashworth scale scores versus the 2U/kg group (primary outcome: treatment differences of –0.4 [p=0.012] and –0.7 [p<0.001] respectively). All groups improved on Physician Global Assessment and children in all groups achieved their treatment goals at least as expected. Therapeutic benefits were sustained during cycles 2 to 4; muscular weakness was the only treatment‐related adverse event reported in at least one child/group (4.3% and 5.7% vs 1.4% respectively). INTERPRETATION: Treatment with 8U/kg or 16U/kg abobotulinumtoxinA significantly reduced upper limb spasticity versus the 2U/kg control dose. Therapeutic benefits of abobotulinumtoxinA plus HETP were sustained with repeat treatment cycles. WHAT THIS PAPER ADDS: AbobotulinumtoxinA injections significantly reduced upper limb spasticity in children with cerebral palsy. Children treated with abobotulinumtoxinA and targeted home exercises showed global improvement and goal attainment. Benefits were sustained over 1 year with repeat cycles of abobotulinumtoxinA and home exercises. AbobotulinumtoxinA injections into the upper limb were well tolerated over 1 year.
format Online
Article
Text
id pubmed-8048784
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-80487842021-04-20 Efficacy and safety of abobotulinumtoxinA for upper limb spasticity in children with cerebral palsy: a randomized repeat‐treatment study Delgado, Mauricio R Tilton, Ann Carranza‐Del Río, Jorge Dursun, Nigar Bonikowski, Marcin Aydin, Resa Maciag‐Tymecka, Iwona Oleszek, Joyce Dabrowski, Edward Grandoulier, Anne‐Sophie Picaut, Philippe Dev Med Child Neurol Original Articles AIM: To assess the efficacy and safety of repeat abobotulinumtoxinA injections in reducing upper limb spasticity in children with cerebral palsy (CP). METHOD: This was a double‐blind, repeat‐cycle study (NCT02106351) in children with CP (2–17y). Children were randomized to receive 2U/kg (control), 8U/kg, or 16U/kg abobotulinumtoxinA injections into the target muscle group (wrist or elbow flexors) and additional muscles alongside occupational therapy via a home‐exercise therapy program (HETP; minimum five 15min sessions/wk). Children received 8U/kg or 16U/kg plus HETP in cycles 2 to 4. RESULTS: During cycle 1, 210 children (126 males, 84 females; mean age [SD] 9y [4y 5mo], range 2–17y; n=70/group) had at least one upper limb abobotulinumtoxinA injection and 209 complied with the HETP. At week 6 of cycle 1, children in the 8U/kg or 16U/kg groups had significantly lower Modified Ashworth scale scores versus the 2U/kg group (primary outcome: treatment differences of –0.4 [p=0.012] and –0.7 [p<0.001] respectively). All groups improved on Physician Global Assessment and children in all groups achieved their treatment goals at least as expected. Therapeutic benefits were sustained during cycles 2 to 4; muscular weakness was the only treatment‐related adverse event reported in at least one child/group (4.3% and 5.7% vs 1.4% respectively). INTERPRETATION: Treatment with 8U/kg or 16U/kg abobotulinumtoxinA significantly reduced upper limb spasticity versus the 2U/kg control dose. Therapeutic benefits of abobotulinumtoxinA plus HETP were sustained with repeat treatment cycles. WHAT THIS PAPER ADDS: AbobotulinumtoxinA injections significantly reduced upper limb spasticity in children with cerebral palsy. Children treated with abobotulinumtoxinA and targeted home exercises showed global improvement and goal attainment. Benefits were sustained over 1 year with repeat cycles of abobotulinumtoxinA and home exercises. AbobotulinumtoxinA injections into the upper limb were well tolerated over 1 year. John Wiley and Sons Inc. 2020-11-18 2021-05 /pmc/articles/PMC8048784/ /pubmed/33206382 http://dx.doi.org/10.1111/dmcn.14733 Text en © 2020 The Authors. Developmental Medicine & Child Neurology published by John Wiley & Sons Ltd on behalf of Mac Keith Press https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Delgado, Mauricio R
Tilton, Ann
Carranza‐Del Río, Jorge
Dursun, Nigar
Bonikowski, Marcin
Aydin, Resa
Maciag‐Tymecka, Iwona
Oleszek, Joyce
Dabrowski, Edward
Grandoulier, Anne‐Sophie
Picaut, Philippe
Efficacy and safety of abobotulinumtoxinA for upper limb spasticity in children with cerebral palsy: a randomized repeat‐treatment study
title Efficacy and safety of abobotulinumtoxinA for upper limb spasticity in children with cerebral palsy: a randomized repeat‐treatment study
title_full Efficacy and safety of abobotulinumtoxinA for upper limb spasticity in children with cerebral palsy: a randomized repeat‐treatment study
title_fullStr Efficacy and safety of abobotulinumtoxinA for upper limb spasticity in children with cerebral palsy: a randomized repeat‐treatment study
title_full_unstemmed Efficacy and safety of abobotulinumtoxinA for upper limb spasticity in children with cerebral palsy: a randomized repeat‐treatment study
title_short Efficacy and safety of abobotulinumtoxinA for upper limb spasticity in children with cerebral palsy: a randomized repeat‐treatment study
title_sort efficacy and safety of abobotulinumtoxina for upper limb spasticity in children with cerebral palsy: a randomized repeat‐treatment study
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8048784/
https://www.ncbi.nlm.nih.gov/pubmed/33206382
http://dx.doi.org/10.1111/dmcn.14733
work_keys_str_mv AT delgadomauricior efficacyandsafetyofabobotulinumtoxinaforupperlimbspasticityinchildrenwithcerebralpalsyarandomizedrepeattreatmentstudy
AT tiltonann efficacyandsafetyofabobotulinumtoxinaforupperlimbspasticityinchildrenwithcerebralpalsyarandomizedrepeattreatmentstudy
AT carranzadelriojorge efficacyandsafetyofabobotulinumtoxinaforupperlimbspasticityinchildrenwithcerebralpalsyarandomizedrepeattreatmentstudy
AT dursunnigar efficacyandsafetyofabobotulinumtoxinaforupperlimbspasticityinchildrenwithcerebralpalsyarandomizedrepeattreatmentstudy
AT bonikowskimarcin efficacyandsafetyofabobotulinumtoxinaforupperlimbspasticityinchildrenwithcerebralpalsyarandomizedrepeattreatmentstudy
AT aydinresa efficacyandsafetyofabobotulinumtoxinaforupperlimbspasticityinchildrenwithcerebralpalsyarandomizedrepeattreatmentstudy
AT maciagtymeckaiwona efficacyandsafetyofabobotulinumtoxinaforupperlimbspasticityinchildrenwithcerebralpalsyarandomizedrepeattreatmentstudy
AT oleszekjoyce efficacyandsafetyofabobotulinumtoxinaforupperlimbspasticityinchildrenwithcerebralpalsyarandomizedrepeattreatmentstudy
AT dabrowskiedward efficacyandsafetyofabobotulinumtoxinaforupperlimbspasticityinchildrenwithcerebralpalsyarandomizedrepeattreatmentstudy
AT grandoulierannesophie efficacyandsafetyofabobotulinumtoxinaforupperlimbspasticityinchildrenwithcerebralpalsyarandomizedrepeattreatmentstudy
AT picautphilippe efficacyandsafetyofabobotulinumtoxinaforupperlimbspasticityinchildrenwithcerebralpalsyarandomizedrepeattreatmentstudy
AT efficacyandsafetyofabobotulinumtoxinaforupperlimbspasticityinchildrenwithcerebralpalsyarandomizedrepeattreatmentstudy